The Current Understanding of and Treatment Paradigm for Newly-Diagnosed <i>TP53</i>-Mutated Acute Myeloid Leukemia
About 10% of newly diagnosed and 20–30% of therapy-related acute myeloid leukemia (AML) harbors a <i>TP53</i> mutation (<i>mTP53</i>-AML). Unfortunately, this biological subset predicts one of the worst prognoses among patients with AML, specifically a median overall survival of about 7 months with...
-д хадгалсан:
| Үндсэн зохиолчид: | , , , |
|---|---|
| Формат: | Artigo |
| Хэл сонгох: | Inglês |
| Хэвлэсэн: |
MDPI AG
2021-12-01
|
| Цуврал: | Hemato |
| Нөхцлүүд: | |
| Онлайн хандалт: | https://www.mdpi.com/2673-6357/2/4/51 |
| Шошгууд: |
Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!
|